Reteplase biosimilar (Jiangsu Wuzhong) | Interleukin Related interleukin-related.com

Product Name :
Reteplase biosimilar (Jiangsu Wuzhong)

Search keywords :
Reteplase

drugId :
null

Target Vo:
Plasminogen

Target Vo Short Name :
PLG

Moa_Name:
Plasminogen stimulants

First Approval Country :
Mainland China

First Approval Date Filter:
2009

Origin Company_Name :
Jiangsu Wuzhong Pharmaceutical Group Co Ltd

Active Company_Name :
Jiangsu Wuzhong Pharmaceutical Group Co Ltd

Active Indication_Name:
Myocardial Infarction

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
MMP12 Rabbit mAb Epigenetics
PI3 Kinase p110 beta Antibody site
STAT5b Antibody: STAT5b Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 90 kDa, targeting to STAT5b. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts